The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

"AbbVie expands North Chicago API production with $195m investment" was originally created and published by Pharmaceutical ...

AbbVie, a global leader in life sciences, announced Tuesday the company’s is investing $195 million to expand its North ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Abbott Laboratories spinoff AbbVie will ...

NORTH CHICAGO Governor JB Pritzker, AbbVie, and the Illinois Department of Commerce and Economic Opportunity (DCEO) today ...

Governor JB Pritzker, AbbVie, and the Illinois Department of Commerce and Economic Opportunity (DCEO) have announced a ...

As pharma companies big and small play up their U.S. investment plans during the second Trump administration, the particulars ...

AbbVie, the maker of Botox, Humira, and Rinvoq, will invest $195 million to expand its North Chicago manufacturing facility, creating at least 50 new jobs within the next three years.

Drugmaker AbbVie plans to construct a $195 million facility near its headquarters in North Chicago to manufacture active pharmaceutical ingredients, The Chicago Tribune reported Aug. 12. Construction ...